ADVERTISEMENT



Google       
Call (866) 635-2689 for a free Personal Injury evaluation by attorney in your area.

Home -> Law Blog Directory -> Personal Injury Law Blogs -> Drug Injury Watch

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Personal Injury Law

: Drug Injury Watch

Diet Drug Meridia Has Possible Cardiovascular Risks, Including Stroke, Heart Attack, And Cardiac Death

By Tom Lamb

ADVERTISEMENTS

FDA Early Communication About Meridia (Sibutramine) Side Effects Issued by Agency In November 2009

(Posted by Tom Lamb at DrugInjuryWatch.com)

On November 20, 2009 the FDA issued an "Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride)" to let patients and their doctors know about a possible increased risk for adverse cardiovascular events associated with the obesity drug Meridia.

As background, Meridia was approved by FDA in 1997 for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with a reduced calorie diet.  Meridia is marketed by Abbott Laboratories in the U.S.

A November 21, 2009 article, "Early Data Link Diet Drug to MI, Stroke, and Cardiac Death", published online by MedPage Today, provides a good summary of the basis for this Meridia safety alert:

Preliminary analysis of data from a placebo-controlled study of sibutramine (Meridia) suggested an excess risk of cardiovascular events including myocardial infarction and cardiac death among patients taking the diet drug, according to the FDA.

The findings come from a trial of 10,000 high-risk patients who were randomized to sibutramine or placebo. The FDA said there was a 1% absolute difference in the rate of heart attack, stroke, resuscitated cardiac arrest, or death with 11% of the sibutramine patients reaching that endpoint versus 10% of the placebo patients.

The difference, while small, "is higher than expected, suggesting that sibutramine is associated with an increased cardiovascular risk in the study population," the FDA said....

The findings come from the SCOUT trial (Sibutramine Cardiovascular Morbidity/Mortality Outcomes in Overweight or Obese Subjects at Risk of a Cardiovascular Event) which had a combined primary endpoint of heart attack, stroke, resuscitated cardiac arrest, or death.

The study, begun in 2002, was conducted as part of a postapproval agreement with the agency that oversees drug approvals for the European Union.

We last wrote about cardiovascular side effects being associated with Meridia use back in October 2007, when Health Canada provided an update on reports of suspected Meridia adverse reactions.

P.S.  An update by means of this December 3, 2009 Reuters article: "US consumer group asks FDA to ban Abbott diet drug -- Public Citizen says Meridia increases heart risks".  (12/4/09)

______________________________________________________________________________

DrugInjuryLaw.com: Legal Information And News About Prescription Drug Side Effects

Full post as published by Drug Injury Watch on November 30, 2009 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Related Law Articles

Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0132 secs (new cache)